Gilead Sciences, Inc. (NASDAQ:GILD) Is a Favorite Amongst Institutional Investors Who Own 86%
Stocks With the Highest Consensus of Expected ROE Growth, Goldman Sachs Says
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
Top 4 Health Care Stocks That May Keep You Up At Night
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial Due To The Presence Of A Glass Particle
Express News | FDA: Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury (Remdesivir) for Injection 100 Mg/Vial Due to the Presence of a Glass Particle
Yuhan Signs KRW107.7 Billion Deal With Gilead Sciences for HIV Treatment Raw Material Supply
Novo CEO Faces Sanders Over GLP-1 Drug Prices. All of Pharma Should Tune In. -- Barrons.com
Gilead Sciences, Verizon Communications And ManpowerGroup Are Winners For Passive Income
Sword of Justice! The US FTC sues three major pharmaceutical "middlemen", vows to correct the distorted profit chain.
The USA's FTC announced on its official website that it has filed a lawsuit against three major "pharmacy benefit managers" and their affiliated organizations, accusing them of engaging in anti-competitive and unfair kickback practices. FTC also "clearly stated" in the declaration its deep concern about the roles played by eli lilly and co, novo-nordisk a/s, sanofi, and other insulin pharmaceutical companies, and the competition bureau may recommend prosecuting these pharmaceutical companies in future enforcement actions.
Gilead Sciences Unusual Options Activity For September 20
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Wells Fargo's 'Value Equity List' – Stocks With Potential That Trade at a Discount
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Kyverna Therapeutics Names Warner Biddle CEO
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies analyst Michael Yee maintains $Gilead Sciences(GILD.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 43.3% and a